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https://doi.org/10.1016/j.stemcr.2018.09.007SUMMARYMultiple system atrophy (MSA) is a progressive neurodegenerative disease that affects several areas of the CNS, whose pathogenesis is still
widely unclear and for which an effective treatment is lacking. We have generated induced pluripotent stem cell-derived dopaminergic
neurons from fourMSA patients and four healthy controls and from twomonozygotic twins discordant for the disease. In this model, we
have demonstrated an aberrant autophagic flow and a mitochondrial dysregulation involving respiratory chain activity, mitochondrial
content, and CoQ10 biosynthesis. These defective mechanisms may contribute to the onset of the disease, representing potential ther-
apeutic targets.INTRODUCTION
Multiple system atrophy (MSA) is a severe and progressive
neurodegenerative disease. Parkinsonism, cerebellar ataxia,
dysautonomia, and pyramidal features are the main clin-
ical hallmarks. According to the predominant symptom-
atology at onset, either parkinsonian or cerebellar, two
different subtypes of the disease can be distinguished:
MSA-P and MSA-C, respectively (Fanciulli and Wenning,
2015).
Althoughmany preclinical and clinical trials are in prog-
ress (Valera et al., 2016), an effective treatment is still
lacking.
Neuropathologically, MSA is characterized by atrophy
mainly in the putamen in MSA-P and in the cerebellum,
middle cerebellar peduncles, and pontine basis in MSA-C.
a-Synuclein accumulation is the neuropathological hall-
mark of the disease. Differently fromother a-synucleinopa-
thies, it occurs mainly in oligodendrocytes in the form of
glial cytoplasmic inclusions. However, a-synuclein aggre-
gates can be detected also in glial nuclei, neuronal cyto-
plasm, neuronal nuclei, and astroglial cytoplasm. More-Stem Cell Reports j
This is an open access article under the Cover, astrogliosis and microglial activation are common
findings in MSA. Despite the peculiarity of oligodendrog-
lial involvement, neuronal systems are strongly affected.
A prominent degeneration of striatonigral pathway (both
striatal medium spiny neurons and substantia nigra dopa-
minergic neurons) is observed in MSA-P. MSA-C displays
a remarkable degeneration of Purkinje cells and cerebello-
pontine fibers; however, substantia nigra is also affected
(Jellinger, 2014).
The role of mitochondrial dysfunction in the onset and
progression of MSA has been debated. The most direct evi-
dence supporting this scenario is the report ofmutations in
COQ2, a gene involved in the synthesis of CoenzymeQ10
(CoQ10), in familial and sporadic MSA cases (Multiple-Sys-
tem Atrophy Research Collaboration, 2013), but this
finding has not been replicated in independent MSA
cohorts (Sharma et al., 2014; Schottlaender et al., 2014;
Ronchi et al., 2016). The assessment of the activity of respi-
ratory chain complexes in autoptic substantia nigra and
platelets of patients has not provided significant results
(Gu et al., 1997). Two independent groups have recently
described a reduction of CoQ10 levels selectively inVol. 11 j 1185–1198 j November 13, 2018 j ª 2018 The Author(s). 1185
C BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1. Main Clinical Features of Subjects Involved in the
Study
Patient
Code Diagnosis Sex
Age at
Biopsy
(Years)
Age at
Onset
(Years)
Familial
History
P1 MSA-P F 78 68 no
P2 MSA-P M 55 52 no
C1 (AT) MSA-C F 59 55 no
C2 MSA-C F 60 56 no
CTR1 – M 24 – no
CTR2 – F 60 – no
CTR3 – M 68 – no
CTR4 – F 80 – no
UT – F 59 – nocerebellum of MSA patients without mutations in COQ2,
but not in striatum, frontal cortex, or occipital cortex
(Schottlaender et al., 2016; Barca et al., 2016). Nevertheless,
the activity level of complexes I + III and II + III, closely
related to CoQ10, have not shown significant differences.
Furthermore, the amount of two enzymes involved in
CoQ10 synthesis (PDSS1 and COQ5) has been found to
be reduced in MSA brains (Barca et al., 2016).
Upregulation of autophagy is another feature that has
been observed in autoptic MSA samples (Schwarz et al.,
2012; Tanji et al., 2013).
Few models of MSA have been developed, mainly repre-
sented by transgenic mice with overexpression of human
a-synuclein in oligodendrocytes (Shults et al., 2005; Kahle
et al., 2002; Yazawa et al., 2005). Although these models
have allowed dissection of some important aspects of
MSA pathogenesis, they cannot recapitulate all the aspects
of human pathology. Indeed, a-synuclein is artificially
overexpressed and the role of other cells, including neu-
rons, can be underestimated.
Induced pluripotent stem cells (iPSCs), whose generation
has been described only a decade ago (Takahashi and Yama-
naka, 2006), have been used to model several neurodegen-
erative disorders, such as Alzheimer’s disease, Huntington’s
disease, and amyotrophic lateral sclerosis (Ross and Aki-
mov, 2014). Both idiopathic and familial (LRRK2, PINK1,
PRKN, GBA, and SNCA) Parkinson’s disease has been
modeled as well (Torrent et al., 2015).
A single iPSC-based study has been reported so far,
aiming to differentiate MSA-derived iPSCs toward oligo-
dendrocytes (Djelloul et al., 2015). These experiments
have provided evidence for a-synuclein expression in
differentiating oligodendrocytes. However, this study has1186 Stem Cell Reports j Vol. 11 j 1185–1198 j November 13, 2018not explored the cellular and molecular pathogenic events
in MSA neurons.
In this perspective, we have established an iPSC-based
neuronal in vitro model of MSA and have demonstrated
mitochondrial dysregulation and impaired autophagy in
patients’ neurons that can contribute to pathogenesis.RESULTS
Generation and Characterization of iPSCs from MSA
Patients and Controls
We generated iPSCs from skin fibroblasts of four patients
affected with MSA (two MSA-P and two MSA-C) and five
unaffected subjects, including the healthy monozygotic
twin of one of theMSA-C patients (MSA-C1/AT). Diagnosis
of probable MSA was performed according to widely
accepted clinical criteria (Gilman et al., 2008). The main
clinical features of the subjects are described in Table 1.
All subjects were negative for mutations in genes
commonly involved in Parkinson’s disease (LRRK2, GBA,
and SNCA), multiplication of SNCA gene, and ATXN1,
ATXN2, ATXN3, ATXN8, and PPP2R2B pathological re-
peats. Genomic rearrangements were excluded by CGH
array performed on DNA from blood. As previously re-
ported (Ronchi et al., 2016), a homozygous variant in
COQ2 gene (p.A43G) was found in one patient (MSA-C2).
However, the mutation did not affect respiratory chain ac-
tivity in muscle and CoQ10 amount in muscle and
fibroblasts.
iPSCs were generated from skin fibroblasts through a
non-integrating reprogramming method based on the
expression of factors OCT4, SOX2, KLF4, and C-MYC.
Different clones of iPSCs were isolated and expanded.
Immunocytochemistry demonstrated that most of the
cells in all iPSC clones expressed the pluripotency markers
SSEA-4 andOCT4 (Figure 1A). The karyotype of all the lines
was assessed to exclude genetic rearrangements due to the
reprogramming process (Figure 1B). RT-PCR analysis
showed a high expression of the pluripotency markers
OCT4 and NANOG in all iPSC lines compared with fibro-
blasts (Figure 1C).Generation and Characterization of iPSC-Derived
Dopaminergic Neurons
All iPSC lines were differentiated toward dopaminergic
neurons through an already described protocol (Zhang
et al., 2014), which allows the generation of tyrosine hy-
droxylase (TH)-positive neurons with high efficiency.
At 35 days in vitro (DIV) most of the cells were positive
for the neuronal marker TUJ1 and more than 55% of
TUJ1-positive cells were also positive for the catecholamin-
ergic marker TH, as assessed by immunocytochemistry
Figure 1. Characterization of iPSCs
(A) ICC showing positivity of iPSC lines for the stem cell markers SSEA4 and OCT4. Scale bar, 75 mm.
(B) Karyotype analysis of iPSC lines aimed to exclude major genetic rearrangements due to the reprogramming process.
(C) qPCR demonstrating high expression levels of stem cell-related genes OCT4 and NANOG in iPSCs compared with fibroblasts.
Data are expressed as means ± SEM.(Figure 2A and Table S1). At 50DIV themajority of differen-
tiated cells was also positive for the neuronal marker MAP2
(Figure 2B and Table S1). These values are in line with the
ones described in the applied protocol.
RT-PCR was performed at 35 DIV. All the cell lines highly
expressed the markers TUBB3, MAP2, and TH compared
with fibroblasts and iPSCs (Figure 2C).
TUJ1 expression at 35 DIV was confirmed by a robust
signal detected at western blot, which was absent in fibro-
blasts (Figure 2D). Western blot also demonstrated a high
amount of tyrosine hydroxylase in all neuronal lines at
70 DIV (Figure S1A).
To verify a mature neuronal identity, we performed elec-
trophysiology. At 56 DIV evoked action potentials and
spontaneous firing activity in neurons were detected (Fig-
ures 3A and 3B), and inward and outward currents were re-
corded (Figure 3C). Post-synaptic activity was evaluated at
70 DIV, but spontaneous post-synaptic potentials were
rarely observed with the exception of low amplitude spikes
(Figure 3D).To assess the full maturation of neurons, we evaluated
three lines of iPSC-derived neurons (MSA-P2, MSA-C2,
and CTR1) for sphingolipid composition (Scho¨ndorf
et al., 2014) at two differentiation steps, 35 DIV and 70
DIV (Figure 3E; Tables S2 and S3). Differentiated iPSCs con-
tained all the polysialogangliosides found in the CNS. The
radioactivity associatedwith gangliosides ranged from16%
to 22% of the total radioactivity associated with the sphin-
golipid content, and quantitatively was in the range from
1.5 to 2.7 nCi/mg of cellular protein. These data resemble
those obtained from rat granule cells differentiating in cul-
ture (Prinetti et al., 2001) and suggest that the analyzed cell
population is enriched with fully differentiated neurons.
Mature MSA Neurons Display Severe Signs of Cellular
Suffering
To investigate the presence of defects in neuronal matura-
tion and survival in patients, we assessed the level of spe-
cific proteins through western blot: synapsin I, synapsin
III, synaptophysin (synaptic markers), and TAU (neuriteStem Cell Reports j Vol. 11 j 1185–1198 j November 13, 2018 1187
Figure 2. Characterization of iPSC-Derived
Dopaminergic Neurons: First Part
(A) ICC showing positivity for the neuronal marker
TUJ1 and the catecholaminergic marker TH in the
majority of iPSC-derived neurons at 35 DIV. Scale
bar, 50 mm.
(B) ICC showing positivity for the neuronal marker
MAP2 in the majority of iPSC-derived neurons at
50 DIV. Scale bar, 75 mm.
(C) qPCR demonstrating high expression levels of
the neuronal markers TUBB3 and MAP2 and of the
catecholaminergic marker TH in iPSC-derived
neurons at 35 DIV compared with fibroblasts and
iPSCs.
(D) Western blot showing high protein amount of
the neuronal marker TUJ1 in iPSC-derived dopa-
minergic neurons at 35 DIV compared with fibro-
blasts. AT, affected twin; UT, unaffected twin.
Data are expressed as means ± SEM. See also
Figure S1 and Table S1.
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Figure 3. Characterization of iPSC-Derived Dopaminergic Neurons: Second Part
(A) Current clamp recordings in whole-cell configuration of a representative neuron differentiated from MSA-P1 iPSCs at 56 DIV, showing
evoked action potentials. On the right the maximal firing rate is shown, obtained injecting 260 pA of current.
(B) Spontaneous firing activity recorded in current clamp whole-cell configuration. Action potentials are fired at a frequency of 2–6 Hz.
(C) Representative traces of voltage-clamp recordings of inward and outward currents. Neurons were stimulated with voltage steps of
20 mV starting from 0 mV to 80 mV.
(D) Spontaneous post-synaptic potentials recorded in voltage-clamp whole-cell configuration from iPSC-derived neurons of MSAP2 at
70 DIV. Neurons were clamped at70 mV and did not show spontaneous post-synaptic potentials, with the exception of few spikes of low
amplitude.
(E) Sphingolipid composition of iPSC-derived neurons in aqueous phase. Digital autoradiography of HPTLC performed using the solvent
system 0.2% chloroform/methanol/calcium chloride 50:42:11 (v/v/v).
See also Tables S2 and S3.protein) (Figures 4A, 4B, and S1B). At 70 DIV MSA neurons
showed a significant lower level of TAU (p < 0.001) and syn-
apsin I (p < 0.001) compared with controls, and the twins
showed a similar behavior. Data at 70 DIV were also
normalized for the neuronal marker TUJ1, confirming
TAU reduction in patients (p < 0.01) (Figure S1C). qPCR
demonstrated that the observed Tau protein reduction in
MSA was not due to low MAPT mRNA expression levels
(Figure S1D).
a-Synuclein protein amount was not different between
patients and controls (Figure 4C).
Autophagy Is Impaired in MSA Neurons
The level of autophagy-related proteins was investigated
before and after treatment with bafilomycin A1, a V-ATPaseinhibitor which causes block of the fusion between the au-
tophagosome and the lysosome (Klionsky et al., 2012).
LC3-II amount was significantly higher in patients than
in controls (p < 0.05), suggesting an autophagic activation.
Furthermore, the autophagic flux proved to be more effi-
cient in controls, as demonstrated by a significant differ-
ence in the ratio between LC3-II level after bafilomycin
treatment and LC3-II basal level (p < 0.05). Interestingly,
the two twins discordant for the disease showed a similar
behavior (Figure 5A). Decreased LAMP1 and increased
p62 were detected in patients (Figure S2A).
In addition, we assessed the activity of five lysosomal en-
zymes (GBA1, b-galactosidase, b-hexosaminidase, a-man-
nosidase, b-mannosidase) in neurons. GBA1, b-galactosi-
dase, and b-hexosaminidase were similar in patients andStem Cell Reports j Vol. 11 j 1185–1198 j November 13, 2018 1189
Figure 4. Evaluation of Neuronal Markers
(A) Western blot showing TAU, synaptophysin, synapsin I, synapsin III, a-synuclein, and GAPDH in neurons at 70 DIV.
(B) Graphs showing quantifications of TAU, synaptophysin, synapsin I, and synapsin III in neurons at 70 DIV (normalized for GAPDH).
(C) Graphs showing the amount of a-synuclein in neurons at 35 and 70 DIV measured through western blot and normalized for GAPDH. AT,
affected twin; UT, unaffected twin.
Data are expressed as mean ± SEM. *p < 0.05; ***p < 0.001. Three independent experiments were performed for each clone. See also
Figure S1.controls. By contrast, the activity of a-mannosidase and
b-mannosidase proved to be reduced in patients (p <
0.001 for both the enzymes). This finding was confirmed
in the two twins (Figure 5B).
Mitochondrial Functioning Is Significantly Altered in
MSA Neurons
The activity of respiratory chain complexes I, II, I + III, II +
III, and IV was investigated through spectrophotometric
analyses. Values were normalized for the activity of citrate
synthase (CS), a matrix enzyme index of mitochondrial
mass. The activity level of complexes II and II + III was
significantly lower in patients (p < 0.01 and p < 0.001,
respectively) and a trend of reduction was observed for
complexes I + III. A similar behavior was observed in the
twins (Figure 6A).
To assess whether the mitochondrial respiratory enzyme
activity reduction was associated with reduced protein
steady-state levels, we assessed the amounts of complex I,
complex II (SDHA, SDHB), complex III, complex IV, and1190 Stem Cell Reports j Vol. 11 j 1185–1198 j November 13, 2018complex V by western blot and normalized them for the
mitochondrial structural protein TOMM20. The amount
of complexeswas not reduced, indicating that the impaired
activity was not related to the level of mitochondrial pro-
tein. Interestingly, complex II (both SDHA and SDHB sub-
units) and complex III were significantly more expressed
in patients, suggesting a possible compensatory mecha-
nism (Figures 6B and 6C).
To explore the reason for decreased activity of complexes
II + III inMSA, we assessed the amount of CoQ10 and of the
enzymes involved in CoQ10 synthesis (PDSS1, PDSS2,
COQ2, COQ4, COQ5, COQ6, COQ7, ADCK3/COQ8A,
andCOQ9). CoQ10 levels were similar between the groups,
while an increased amount of CoQ10 biosynthetic en-
zymes (PDSS1, PDSS2, COQ4, and ADCK3/COQ8A) was
detected in patients (Figures 6F, 6G, and S2B).
To assess whether the higher amount of mitochondrial
respiratory enzymes and CoQ10 biosynthetic enzyme
levels was also accompanied by increased mitochondrial
mass, we evaluated the level of TOMM20, an outer
Figure 5. Evaluation of Autophagy
(A) Western blot showing the amount of LC3I, LC3II and Actin in neurons at 35 DIV before and after treatment with bafilomycin (200 nM,
24 hr). The graphs on the right show the basal level of LC3II in neurons (normalized for actin) and the autophagic flux of LC3II (ratio
treated/untreated).
(B) Graphs showing the enzymatic activities of b-glucocerebrosidase GBA1, b-galactosidase, b-hexosaminidase, a-mannosidase, and
b-mannosidase measured in total cell lysates of neurons at 35 DIV. AT, affected twin; UT, unaffected twin.
Data are expressed as mean ± SEM. *p < 0.05; **p < 0.01; ***p < 0.001. Three independent experiments were performed for each clone and
graphs represent pooled data from all the experiments. Two clones were used for each subject, with the exception of a few cases (single
clone). Raw data showing results for each single clone are reported in Figure S5. See also Figures S2 and S3.membrane mitochondrial structural protein, which was
significantly higher in patients (p < 0.05) (Figures 6B and
6D). Confirming this finding,mitochondrial DNA content,
a reliable indicator of mitochondrial mass, was signifi-
cantly upregulated in MSA (p < 0.01) (Figure 6E).
Interestingly, autophagy- andmitochondria-related find-
ings were more pronounced in MSA-P, as demonstrated by
reanalyzing MSA-P and MSA-C groups separately (Figures
S3 and S4).DISCUSSION
The present study aimed to evaluate the pathogenic mech-
anisms of MSA, exploiting the promising model of iPSCs,
so far unexplored in this disease.The efficiency of dopaminergic differentiation was
demonstrated by the high expression of markers of mature
neuronal identity, the analysis of sphingolipid composi-
tion, and electrophysiological records.
At 70 DIV TAU and synapsin I were markedly
decreased in MSA neurons, likely suggesting loss of neu-
rites. Interestingly, only synapsin I was reduced, whereas
synapsin III, described to be highly expressed in extrasy-
naptic regions (Porton et al., 2011), did not display
changes. No differences were observed in the levels of
TAU and synapsin I between patients and controls at
35 DIV, suggesting neuronal damage possibly correlated
with aging.
Impairment of two pathways, autophagy and mitochon-
drial functioning, was observed in MSA neurons in this
study.Stem Cell Reports j Vol. 11 j 1185–1198 j November 13, 2018 1191
(legend on next page)
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Autophagy
Autophagic impairment has been studied in depth in
a-synucleinopathies (Xilouri et al., 2016). A possible
involvement of this pathway has been described both in
brains of patients with Lewy body disease and in mouse
models (Klucken et al., 2012; Yu et al., 2009; Crews et al.,
2010). Furthermore, an upregulation of autophagy has
been described in MSA (Schwarz et al., 2012; Tanji et al.,
2013).
In the present study, the assessment of LC3 II at basal
level and after bafilomycin administration has demon-
strated a dysregulation of autophagy in patients. Moreover,
a defective activity has been found in some lysosomal
enzymes. These data are corroborated by the findings
observed in the two twins.
These results suggest that a generalized autophagic defect
is involved inMSA. Further studies will be crucial to the un-
derstanding of whether autophagic deficiency represents a
primary defect of the disease or is a consequence of other
mechanisms (e.g., protein/lipid accumulation), with a
particular focus on the relationship between autophagy
and a-synuclein.
Mitochondria
Mitochondrial dysfunction has been widely investigated
in Parkinson’s disease, and many clues strongly suggest
an involvement in the pathogenesis (Schapira, 2008).
Furthermore, as reported in detail in the Introduction,
mitochondria have been extensively studied also in
MSA.
The results of the present study support the hypothesis of
mitochondrial involvement in the pathogenesis of the dis-
ease. In particular, they suggest mitochondrial dysfunction
and an upregulation of several mitochondrial pathways,
findings that may be closely related to each other. Indeed,
the generalized mitochondrial upregulation may suggestFigure 6. Evaluation of Mitochondria
(A) Graphs showing activity levels of respiratory chain complexes in
Values are normalized for the activity of citrate synthase.
(B) Western blot performed on all neuronal lines at 35 DIV assessing
(C) Graphs showing the amount of the complexes of respiratory chain
for actin.
(D) Graphs showing the amount of the structural mitochondrial protei
normalized for actin.
(E) Graphs showing mtDNA content in neurons at 35 DIV, measured by
CytB and the nuclear reference gene APP.
(F) Graphs showing CoQ10 levels in neurons at 35 DIV, measured thro
(G) Graphs showing the amount of nine enzymes involved in the synth
and normalized for vinculin: PDSS1, PDSS2, COQ2, COQ4, COQ5, COQ6,
twin.
Data are expressed as mean ± SEM. *p < 0.05; **p < 0.01; ***p < 0.001
graphs represent pooled data from all the experiments. Two clones we
clone). Raw data showing results for each single clone are reported ia mitochondrial attempt to compensate the functional
deficit.
Mitochondrial dysfunction is supported by spectropho-
tometric analyses, which show an impaired activity of res-
piratory chain complexes, in particular complex II and
complexes II + III. On the other hand, the mitochondrial
attempt to counterbalance the functional defect is sug-
gested by the increased mitochondrial mass (assessed
through two independentmethods), the increased amount
of respiratory chain complexes II and III, and the upregula-
tion of several enzymes involved in CoQ10 synthesis.
CoQ10 is a component of the mitochondrial respiratory
chain that shuttles electrons from complexes I and II to
complex III. The involvement of CoQ10 deficiency in the
pathogenesis ofMSA has been previously suggested (Multi-
ple-System Atrophy Research Collaboration, 2013; Schot-
tlaender et al., 2016; Barca et al., 2016). Our finding of an
upregulation of various CoQ10 synthesis enzymes, in
particular those that catalyze the initial reactions of biosyn-
thesis, is consistent with the hypothesis of a compensatory
mechanism. In this case the mechanism is effective, as
CoQ10 was not found to be decreased in MSA neurons.
The result is in line with findings on autoptic samples,
which show a CoQ10 reduction only in cerebellum (Schot-
tlaender et al., 2016; Barca et al., 2016). These datamay sug-
gest that an efficient compensatory mechanism is active in
most brain regions with the exception of cerebellum,
which is particularly susceptible to CoQ10-related diseases
(Quinzii et al., 2007).
In the attempt to provide a comprehensive hypothesis,
we suggest that autophagic and mitochondrial defects
may be related. Autophagic impairmentmay also affectmi-
tophagy, resulting in the accumulation of senescent
damaged mitochondria. These organelles do not correctly
function, as the impaired complexes’ activities show.
Consequently, several feedback mechanisms try toneurons at 35 DIV measured through spectrophotometric analysis.
the amount of respiratory chain complexes, TOMM20, and actin.
in neurons at 35 DIV measured through western blot and normalized
n TOMM20 in neurons at 35 DIV measured through western blot and
qPCR through the simultaneous detection of the mitochondrial gene
ugh HPLC.
esis of CoQ10 in neurons at 35 DIV, measured through western blot
COQ7, ADCK3/COQ8A, and COQ9. AT, affected twin; UT, unaffected
. Three independent experiments were performed for each clone and
re used for each subject, with the exception of a few cases (single
n Figures S6 and S7. See also Figures S2 and S4.
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overcome this functional deficit by upregulating a series of
processes:mitochondrialmass, and synthesis of respiratory
chain subunits and of CoQ10. However, dysfunctional
mitochondria are not able to successfully carry out these
tasks, the result of which is a further accumulation of mal-
functioning mitochondria, which contribute to trigger the
pathological compensatory mechanism in a self-propa-
gating fashion.
This picture prompts us to further investigate the mito-
phagic machinery in detail in order to confirm the connec-
tion between autophagic impairment and mitochondrial
defect.Conclusions
Overall, the present study describes a comprehensive
model of MSA based on iPSC-derived neurons and suggests
innovative perspectives for the comprehension of the
pathogenesis of this disease.
In particular, a remarkable impairment of the autophagic
machinery and of specific mitochondrial pathways has
emerged from the study.
These results provide an original contribution for the
comprehension of a disease whose mechanisms are almost
completely unknown and lay the foundations for future
analyses.
Further investigation will explore a-synuclein patholog-
ical behavior, the lysosomal defect (with a particular focus
on the relationship between autophagy and a-synuclein),
and mitophagy, to corroborate the possible link between
autophagic impairment and mitochondrial dysfunction.
Furthermore, the evaluation of the same pathways also in
iPSC-derived oligodendrocytes and in neuron-oligoden-
drocyte co-cultures may shed light on the complex pathol-
ogy observed in patients and on cell-to-cell interaction.
All of these mechanisms can represent potential thera-
peutic targets for this still incurable disease.EXPERIMENTAL PROCEDURES
Ethical Issues
The present study, which involves human samples, was performed
in compliance with Helsinki Declaration. National legislation and
institutional guidelines were observed. Written informed consent
was obtained from all the subjects involved in the study according
to local ethical guidelines (approved by ethical committee at the
IRCCS Foundation Ca’ Granda Ospedale Maggiore Policlinico, Mi-
lan, Italy).Skin Biopsies and Fibroblast Expansion
Skin biopsies were obtained through a punch from the ventral
surface of the right arm. The skin was previously disinfected with
lodopovidone and anesthetized with ice spray. Fibroblasts were
isolated from the biopsies and expanded. Fibroblasts were cultured1194 Stem Cell Reports j Vol. 11 j 1185–1198 j November 13, 2018in Dulbecco’s modified Eagle’s medium (DMEM) supplemented
with fetal bovine serum (15%), penicillin/streptomycin (1%),
and amphotericin B (1%).
iPSC Generation and Expansion
iPSCs were generated from fibroblasts through a commercially
available kit (CytoTune-iPS 2.0 Sendai Reprogramming Kit,
Thermo Fisher). Fibroblasts were incubated with virus for 24 hr.
After another 6 days of culture, cells were detached, plated on
feeder-coated 6-well costars, and maintained in a culture medium
suitable for pluripotent stem cells (Essential 8 Medium, Thermo
Fisher). When colonies appeared, they were transferred to Matri-
gel-coated culture dishes and expanded.
Karyotype Analysis
After adding colchicine, cells were processed with a hypotonic so-
lution (0.6% sodium citrate and 0.13% potassium chloride) and
fixedwith amethanol/acetic acid solution (ratio 3:1). A quinacrine
solution was used to obtain Q-banding and cell metaphases were
acquired under a fluorescence microscope at 1003magnification;
metaphases were analyzed with a MetaSystems-Ikaros analytical
system. About 30 metaphases from at least two independent cul-
tures were analyzed according to the ISCN and to the European
General Guidelines and Quality Assurance for Cytogenetics at
approximately 300–400 band level.
Immunocytochemistry
Immunocytochemistry was performed following standard proced-
ures. Slide-adherent cells were rinsed in 13 PBS (3 times), incu-
bated in 4% paraformaldehyde for 10 min, and rinsed in 13 PBS
(3 times). Cells were then incubated in blocking solution (13
PBS containing 10% BSA and 0.3% Triton) for 1 hr and in satura-
tion solution (13 PBS containing 3% BSA) containing primary
antibody at proper concentration overnight at 4C. Cells were
then incubated in saturation solution containing secondary anti-
body and DAPI at proper concentration for 2 hr and rinsed in 13
PBS (3 times). Finally, the slides were mounted. Images were
obtained through the confocal system Leica TCS SP2 (Leica Micro-
systems). For details of primary and secondary antibodies, see
Table S4.
iPSC Differentiation toward Dopaminergic Neurons
iPSCs were differentiated toward dopaminergic neurons according
to the protocol described by Zhang et al. (2014) (with mild
changes) which, in turn, is based on the protocol described by
Kriks et al. (2011). Cells were cultured in proper media supple-
mented with specific factors at proper concentrations as follows.
Day 0: KSR differentiation medium (81% DMEM, 15% KSR,
1003 1%non-essential amino acids, 1003 1% b-mercaptoethanol,
1003 1% penicillin/streptomycin, 1003 1% amphotericin) sup-
plemented with 10 mM SB431542 and 100 nM LDN-193189.
Days 1 and 2: KSR differentiation medium supplemented with
10 mM SB431542, 100 nM LDN-193189, 0.25 mM SAG, 2 mM pur-
morphamine, and 50 ng/mL fibroblast growth factor 8b (FGF8b).
Days 3 and 4: KSR differentiation medium supplemented with
10 mM SB431542, 100 nM LDN-193189, 0.25 mM Smoothened
agonist (SAG), 2 mM purmorphamine, 50 ng/mL FGF8b, and
3 mMCHIR99021. Days 5 and 6: 75% KSR differentiation medium
and 25% N2 differentiation medium (97% DMEM, 1003 1% N2
supplement, 1003 1% penicillin/streptomycin, 1003 1% ampho-
tericin) supplemented with 100 nM LDN-193189, 0.25 mM SAG,
2 mM purmorphamine, 50 ng/mL FGF8b, and 3 mM CHIR99021.
Days 7 and 8: 50% KSR differentiationmedium and 50%N2 differ-
entiation medium supplemented with 100 nM LDN-193189 and
3 mMCHIR99021. Days 9 and 10: 25%KSR differentiationmedium
and 75% N2 differentiation medium supplemented with 100 nM
LDN-193189 and 3 mMCHIR99021. Days 11 and 12: B27 differen-
tiation medium (95% neurobasal medium, 503 2% B27 supple-
ment, 1% Glutamax, 1003 1% penicillin/streptomycin, 1003
1% amphotericin) supplemented with 3 mM CHIR99021,
10 ng/mL brain-derived neurotrophic factor (BDNF), 10 ng/mL
glial cell line-derived neurotrophic factor (GDNF), 1 ng/mL trans-
forming growth factor b3 (TGF-b3), 0.2 mM ascorbic acid, and
0.1 mM cyclic AMP. From day 13 to the end of differentiation:
B27 differentiation medium supplemented with 10 ng/mL BDNF,
10 ng/mL GDNF, 1 ng/mL TGF-b3, 0.2 mM ascorbic acid, and
0.1 mM cyclic AMP. At 20 DIV cells were split using Accutase. For
details of reagents, see Table S7.Western Blot
Proteins were extracted in H2O+ protease inhibitor cocktail
(P2714, Sigma), sonicated two times for 15 s at 50 W, and centri-
fuged for 10 min at 750 3 g. Proteins were quantified through
the Lowrymethod. Samples were prepared in Novex Bolt LDS sam-
ple buffer and Novex Bolt Reducing Agent (Thermo Fisher) and
boiled for 3 min. Proteins (5–30 mg) were loaded in Precast Bolt
Bis-Tris Plus Gels 4%–12% and in Novex Bolt 13 MES/SDS
Running buffer at 200 V for 30 min. Trans-Blot Turbo system
(Bio-Rad) was used for transfer in nitrocellulose membrane. Mem-
branes were blocked with 5% milk (Bio-Rad) or 1% BSA + 10%
horse serum. For CoQ10 synthesis enzymes, proteins were ex-
tracted from cell pellets by sonication in lysis buffer (50 nM Tris-
HCl, 150 mM NaCl, 1 mM EDTA) + protease inhibitor (Complete
Mini, EDTA-free, 11836170001, Roche). Proteins were quantified
through the Bradford system (ThermoScience) and analyzed by
electrophoresis in a Novex 10%–20% Glycine Gel (EC61355, Invi-
trogen) loading 10 mg of protein of each sample. After electropho-
resis, proteins were transferred to a PVC transfer membrane
(IPFL00010, Immobilon-FL). Membranes were blocked in PBT
(PBS with Tween 20) with 5% milk before incubation.
Protein bands were visualized by chemiluminescence using ECL
reagents. Intensity of the bands was quantified with ImageJ (NIH).
Protein amount was normalized for actin, GAPDH, or vinculin. For
details of antibodies, see Table S5.Electrophysiology
Currents and action potentials (APs) were recorded in whole-cell
configuration using an Axopatch 200B Amplifier and pClamp
10.2 software (Molecular Devices). Traces were sampled at 10 kHz
using a Digidata 1322A acquisition Interface (Molecular Devices)
and filtered at 1 kHz. Borosilicate glass pipettes (GB150F-8P, Sci-
ence Products), with a resistance of 4–6 MU, were filled with an
intracellular solution containing 126 mM K-gluconate, 4 mM
NaCl, 10 mM HEPES, 10 mM glucose, 1 mM MgSO4, 0.5 mMCaCl2, 1 mM EGTA, 3 mM ATP (magnesium salt), and 0.1 mM
GTP (sodium salt) (pH 7.2). External solution contained 140 mM
NaCl, 3 mM KCl, 1.2 mM MgCl2, 2 mM CaCl2, 10 mM HEPES,
and 10 mM glucose (pH 7.4). APs were recorded in current-clamp
mode, by first adjusting the membrane potential (Vh) at 65 mV
and then injecting five pulses of increasing intensity. Spontaneous
APs were recorded at the resting membrane potential of the cell,
without current injection. Voltage-dependent ionic currents were
recorded in voltage-clamp mode; cell membrane potential was
clamped at 70 mV and voltage steps lasting 800 ms and ranging
from 80 mV to 60 mV were delivered at 20-mV increments.
Sphingolipid Analysis
[1-3H]Sphingosine (radiochemical purity over 98%; specific radio-
activity 0.86 Ci/mmol) was prepared and standard lipids were ex-
tracted by bovine brain. iPSC-derived neurons were incubated
with 3 3 108 M [1-3H]sphingosine for a 2-hr pulse followed by
a 48-hr chase, dissolving the radioactive precursor of sphingolipids
in culture medium. After chase, cells were harvested and cell
lysates were lyophilized and subjected to lipid extraction with
chloroform/methanol/water 2:1:0.1 (v/v/v). Total lipid extracts
were then subjected to a two-phase partitioning, resulting in the
separation of an aqueous phase containing gangliosides and an
organic phase containing all other lipids. Lipids were separated
by high-performance thin-layer chromatography using the sol-
vent system 0.2% chloroform/methanol/calcium chloride
50:42:11 (v/v/v). Radioactive lipids were detected and quantified
by digital autoradiography (Beta-Imager 2000 instrument,
BioSpace). Identification of lipids after separation was assessed by
co-migration with authentic standards. The radioactivity associ-
ated with individual lipids was determined with M3Vision
software. The radioactivity associated with lipid extracts was deter-
mined by liquid scintillation counting.
DNA and RNA Extraction from Cells and Reverse
Transcription
DNA and RNAwere extracted through commercially available kits
(FlexiGene DNA Kit [Qiagen] and RNeasy Mini Kit [Qiagen],
respectively) following the manufacturer’s instructions. cDNA
was obtained through the commercially available kit Ready-To-
Go You-Prime First-Strand Beads (GE Healthcare), using 1 mg of
RNA for each sample.
qPCR
For each well, 25 mL was prepared as follows. Taqman: 12.5 mL of
TaqMan Universal PCR Master Mix (Thermo Fisher), 6.5 mL of
H2O, 1 mL of primer/probe assay, and 5 mL of 1:10 dilution of
cDNA. SYBRgreen: 12.5 mL of Power SYBR Green PCR Master Mix
(Applied Biosystems), 5 mL of 1:10 dilution of cDNA, forward and
reverse primers at proper concentration, and H2O up to a total vol-
ume of 25 mL. 18S, ACTB and GAPDH were used as housekeeping
genes. Data were analyzed by the DDCt method. A 7500 Real-
Time PCR System was used. For the evaluation of mtDNA content
qPCRwas performed on genomic DNA for the simultaneous detec-
tion of the mitochondrial gene CYTB and the nuclear reference
gene APP (DDCt method). Details of primers and probes are avail-
able in Table S6.Stem Cell Reports j Vol. 11 j 1185–1198 j November 13, 2018 1195
Lysosomal Enzymatic Activity Assays
The fluorogenic substrates used were purchased from Glycosynth:
4-methylumbelliferyl b-D-glucopyranoside (MUB-b-Gluc) for
b-glucocerebrosidase GBA1, 4-methylumbelliferyl b-D-galactopyr-
anoside (MUB-b-Gal) for b-galactosidase, 4-methylumbelliferyl
N-acetyl-b-D-glucuronide (MUG) for b-hexosaminidase, 4-methyl-
umbelliferyl a-D-mannopyranoside (MUB-a-Man) for a-mannosi-
dase, and 4-methylumbelliferyl b-D-mannopyranoside (MUB-
b-Man) for b-mannosidase. iPSC-derived neurons were harvested
and lysed in water containing protease inhibitors. Equal amounts
of cell lysates were transferred to a 96-well microplate. The activ-
ities of b-galactosidase, b-hexosaminidase, a-mannosidase, and
b-mannosidase were measured in McIlvaine buffer (pH 5.2) using
0.5 mM MUB-b-Gal, 0.5 mM MUG, 0.5 mM MUB-a-Man, and
0.5 mM MUB-b-Man, respectively. For GBA1 assay, the cells were
preincubated for 30 min at room temperature in McIlvaine buffer
containing 5 nM AMP-DNM N-(5-adamantane-1-yl-methoxy-
pentyl)-deoxynojirimycin, specific inhibitor of GBA2. After
incubation with the inhibitor, MUB-b-Gluc was added at a final
concentration of 6 mM. The reaction mixtures were incubated at
37C under gentle shaking. The fluorescence was recorded after
transferring 10 mL of the reaction mixtures to a microplate and
adding 190 mL of 0.25 M glycine (pH 10.7).
CoQ10 Dosage
CoQ10 was isolated from pellets with the hexane/ethanol 5:2
extraction technique. The combined hexane extract was dried un-
der slow N2 gas flow and then resuspended in 1-propanol. CoQ10
levels were determined by high-performance liquid chromatog-
raphy (HPLC) on a reverse-phase Symmetry C18 3.5-mm, 4.6 3
150-mm column (Waters), using a mobile phase consisting of
methanol, ethanol, 2-propanol, acetic acid (500:500:15:15), and
50 mM sodium acetate at a flow rate of 0.9 mL/min. The electro-
chemical detection system consisted of an ESA Coulochem III
with a guard cell (upstream of the injector) at +900mV, condition-
ing cell at 600 mV (downstream of the column), followed by the
analytical cell at +500 mV. The CoQ10 concentration was esti-
mated by comparison of the peak area with those of standard solu-
tions of known concentrations.
Spectrophotometric Analysis of the Activity of
Respiratory Chain Complexes
The activities of respiratory chain complexes were measured
through a Lambda 2 PerkinElmer spectrophotometer. Proteins
were extracted at 4C by adding a buffer at pH 7.2 to cell pellets,
sonicating three times at 50 W for 10 s, centrifuging at 750 3 g
for 10min, and recovering the supernatant. Protein concentration
was measured through the Lowry method. Complex I activity
(NADH ubiq.1 red) was measured at 340 nm after preparing a solu-
tion containing 0.1 M K-phosphate (200 mL) (pH 7.5), 100 mM so-
dium azide (10 mL), 1% albumin (100 mL), 2 mM NADH (70 mL),
H2O (610 mL), homogenate (10 mL), 6 mM CoQ1 (5 mL); thereafter
1 mM rotenone (5 mL) was added and the residue activity was sub-
tracted from the total. Complex II activity (Succ. Coq. Red) was
measured at 600 nm after preparing a solution containing 0.1 M
K-phosphate (pH 7) (500 mL), 400 mM succinic acid (40 mL),
0.5 mM 2,6 dichloroindophenol (200 mL), 30 mM KCN (50 mL),1196 Stem Cell Reports j Vol. 11 j 1185–1198 j November 13, 2018H2O (190 mL), homogenate (20 mL), and 15mMCoQ1 (3 mL). Com-
plexes I + III activity (NADH cit C red) was measured at 550 nm af-
ter preparing a solution containing 0.1 M K-phosphate (pH 7.5)
(250 mL), 30 mM KCN (20 mL), 2 mM NADH (120 mL), 1 mM cyto-
chrome c (100 mL), homogenate (20 mL), and H2O (490 mL). Com-
plexes II + III activity (Succ cit C red) was measured at 550 nm after
preparing a solution containing 0.1 M K-phosphate (pH 7.5)
(500 mL), 30mMKCN (20 mL), 400mM succinate (50 mL), 1mMcy-
tochrome c (100 mL), homogenate (30 mL), andH2O (300 mL). Com-
plex IV activity (Cytochrome ox) was measured at 550 nm after
preparing a solution containing 0.1 M K-phosphate (pH 7)
(200 mL), 1% reduced cytochrome c (100 mL), H2O (680 mL), andho-
mogenate (20 mL). Citrate synthase activity was measured at
412 nm after preparing a solution containing 1 mM 5,50-dithio-
bis-(2-nitrobenzoic acid) (100 mL), 10 mM oxaloacetic acid
(50 mL), 10mMacetyl-CoA (30 mL), H2O (800 mL), and homogenate
(20 mL). All the experiments were performed at 30C. For analyses
we used PerkinElmer software. All the activities were normalized
for the activity of citrate synthase.
Quantification and Statistical Analysis
The patients’ and controls’ groups were both composed of four
subjects. The unaffected twin (UT) is an independent cell line
and has not been included in the control group. The affected
twin (AT) has been included also in the patient group, but indepen-
dent experiments have been performed for comparisons with UT.
The number of replicates is indicated in the figure legends.
A two-tailed Student’s t test was used for statistical analyses.
Graphs in figures represent mean ± SEM (with means of controls
and UT = 1, unless otherwise indicated).
For statistical significance *p < 0.05, **p < 0.01, and ***p < 0.001.
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